In a clinical study conducted on 983 samples from 856 patients, MYCO WELL D-ONE® showed a sensitivity of 91.98% and a specificity of 96.44% for the detection of Ureaplasma spp. compared with qPCR. For Mycoplasma hominis, specificity was 98.84%, with an overall accuracy of 96.24%.

The study, published in the European Journal of Clinical Microbiology & Infectious Diseases, evaluated MYCO WELL D-ONE® in patients attending sexual health services in Wales.

The aim was to compare the performance of the culture-based system with reference molecular and microbiological methods and to further investigate the role of antimicrobial susceptibility screening.

Key takeaways from the study

The study included:

  • 856 patients;
  • 983 clinical samples;
  • urine samples and swabs;
  • comparison with multiplex qPCR;
  • culture-based evaluation;
  • confirmation of resistance using AST methods compliant with CLSI criteria;
  • analysis of genetic resistance mechanisms by whole genome sequencing in the resistant isolates identified.

The results showed high specificity for both microorganisms and particularly high sensitivity for Ureaplasma spp.

Performance of MYCO WELL D-ONE for Ureaplasma spp.

Compared with the qPCR method used by the authors as the reference methodology, MYCO WELL D-ONE achieved the following results for Ureaplasma spp.:

Parameter Result
Sensitivity 91.98%
Specificity 96.44%
Positive predictive value 95.60%
Negative predictive value 93.47%
Accuracy 94.40%

The results therefore show a high ability of the culture-based system to detect Ureaplasma spp. in clinical samples compared with qPCR.

Another interesting finding emerges when analysing the sample type.

In urine samples, specificity for Ureaplasma spp. reached 99.27%, with an accuracy of 96.36%.

Performance in the detection of Mycoplasma hominis

For Mycoplasma hominis, the study reported:

Parameter Result
Sensitivity 78.23%
Specificity 98.84%
Positive predictive value 90.65%
Negative predictive value 96.92%
Accuracy 96.24%

Sensitivity was lower than that observed for Ureaplasma spp., while specificity remained very high.

The authors note that a lower culture recovery rate for M. hominis compared with Ureaplasma spp. had already been reported in previous studies of culture-based methods.

Urine or swabs? Bacterial load may vary

The study also analysed the relationship between sample type and bacterial load.

For Ureaplasma spp., 55.9% of positive swabs had a bacterial load above 10⁵ CCU/mL, compared with 5.9% of positive urine samples.

A similar pattern was observed for M. hominis:

  • 40% of positive swabs had a bacterial load >10⁵ CCU/mL;
  • only 7% of positive urine samples exceeded this threshold.

These findings are particularly important when considering antimicrobial susceptibility screening, as the correct inoculum concentration is a key factor for interpretation according to CLSI criteria.

The authors concluded that, under the conditions of the study, urine samples were more suitable for combining culture-based detection with CLSI-compliant AST assessment.

How long does detection take?

The study also compared the time required to detect microorganisms using MYCO WELL D-ONE and titrated culture in specific media.

For Ureaplasma spp. in female patients, the mean detection time was:

  • 27.57 hours with MYCO WELL D-ONE;
  • 28.14 hours with titrated culture.

In male patients, the mean detection time was 34.09 hours with both methods.

For M. hominis, mean detection times were longer, approximately 43–46 hours depending on the group analysed.

No significant differences in detection time were observed between MYCO WELL D-ONE and the comparative culture method.

Antimicrobial resistance: screening and confirmation are not the same

One of the most interesting features of MYCO WELL D-ONE is the possibility of obtaining preliminary information on antimicrobial susceptibility alongside microorganism detection.

However, the study highlights an important distinction.

MYCO WELL D-ONE should be considered a resistance screening tool and not a substitute for MIC confirmation or molecular methods when confirmation of a resistance result is required.

The authors therefore subjected presumptive resistance results to CLSI-compliant AST testing and, in isolates with confirmed resistance, also performed genomic analysis.

The following were identified:

  • two Ureaplasma spp. isolates resistant to levofloxacin;
  • two Ureaplasma spp. isolates resistant to tetracycline;
  • two M. hominis isolates resistant to tetracycline.

Whole genome sequencing associated levofloxacin resistance with the Ser83Leu mutation in the parC gene, while tetracycline resistance was associated with the tet(M) determinant.

The importance of correct reading time

The study also highlighted an important operational aspect.

Reading the wells too late may contribute to results that falsely indicate resistance.

For this reason, results should be interpreted at the appropriate time of the first identification of the microorganism, carefully following the instructions provided for the system.

This confirms that diagnostic quality depends not only on the test itself, but also on correct management of the analytical phase.

What is the role of MYCO WELL D-ONE?

The authors conclude that MYCO WELL D-ONE is a sensitive and specific test for the detection of Ureaplasma spp. and Mycoplasma hominis in genitourinary medicine samples.

qPCR remains the preferred methodology because of its higher sensitivity and its ability to differentiate Ureaplasma species.

However, MYCO WELL D-ONE can provide a culture-based solution in settings where high-throughput molecular testing is unavailable or not economically sustainable, while simultaneously allowing microorganism detection and initial antimicrobial susceptibility screening.

The study therefore represents an important independent validation of the system’s performance in a real-world clinical setting.

Scientific references

Morris DJ, Jones LC, Davies RL, Sands K, Portal E, Spiller OB.
MYCO WELL D-ONE detection of Ureaplasma spp. and Mycoplasma hominis in sexual health patients in Wales.
European Journal of Clinical Microbiology & Infectious Diseases. 2020.
DOI: 10.1007/s10096-020-03993-7.

F.A.Q.

What is MYCO WELL D-ONE?

MYCO WELL D-ONE is a culture-based system developed to detect Ureaplasma spp. and Mycoplasma hominis while simultaneously providing antimicrobial susceptibility screening.

What was the sensitivity of MYCO WELL D-ONE for Ureaplasma spp.?

In the study involving 983 samples, overall sensitivity compared with qPCR was 91.98%.

What was the specificity?

Specificity was 96.44% for Ureaplasma spp. and 98.84% for Mycoplasma hominis.

Does MYCO WELL D-ONE replace qPCR?

No. In the study, qPCR is considered the reference methodology for detection and also provides the ability to differentiate Ureaplasma species. MYCO WELL D-ONE represents a complementary culture-based approach.

Can the antimicrobial susceptibility result be considered an MIC?

No. The system provides antimicrobial susceptibility screening. Results indicating resistance should be confirmed, when required, by MIC determination using CLSI-compliant methods or by molecular methods.

Which sample type proved more suitable in the study?

The authors observed that urine samples more frequently had bacterial loads compatible with correct AST assessment according to CLSI criteria compared with swabs.